Lung cancer is the second most common malignancy and the number one cancer killer in the United States, killing more people than breast, prostate, and colon cancer combined. Approximately 80% of lung cancer-related deaths are directly attributable to smoking, and the risk of lung cancer is related to the duration and intensity of tobacco use. 1 Despite many people quitting smoking, 50% of lung cancers in the United States are diagnosed in former smokers. There is a perception that lung cancer is deserved when the patient has a history of smoking. 2, 3 Because of this stigma, many patients with lung cancer might feel more guilt or shame about their cancer, which could affect their cancer care. Such illness-related stigma is known to impair a patient's self-esteem, socialization, and health care-seeking behavior 4-6 as well as to contribute to a negative mood. 6,7 Stigmatization of one's illness has also been linked with poor compliance with medical treatments, 8, 9 of particular importance for a patient about to receive chemotherapy and/or radiation Noelle K. LoConte, 1 Nicole M. Else-Quest, 2 Jens Eickhoff, 1 Janet Hyde, 1 Joan H. Schiller 3 Abstract PURPOSE: Patients with lung cancer might feel more guilt and shame resulting from previous smoking. This study was designed to determine the levels of guilt and shame among patients with non-small-cell lung cancer (NSCLC) compared with breast and prostate cancer. PATIENTS AND METHODS: Surveys were sent to participants 3 times (at enrollment, 2 months, and 6 months). Patients were eligible if they had stage IV NSCLC, breast cancer, or prostate cancer. The survey included tests of generalized guilt, shame, depression, and anxiety as well as guilt, shame, and embarrassment related to one's cancer. RESULTS: One hundred seventy-two participants completed ≥ 1 questionnaire: 96 patients with NSCLC, 30 patients with breast cancer, and 46 patients with prostate cancer. Of the patients with NSCLC, 91.7% were current or former smokers versus 67.1% of the comparison patients. A composite score of embarrassment related to one's cancer (perceived cancer-related stigma; PCRS) was higher in patients with NSCLC (P < .01). Mean baseline generalized guilt and shame scores were not different among groups and did not change over time. A history of smoking correlated with increased levels of guilt and shame, regardless of tumor type. A personal identification of past behaviors as contributing to cancer correlated with higher levels of guilt, shame, anxiety, and depression. Of the patients with NSCLC, 29.5% felt that their behaviors contributed to their cancer compared with 10.5% of the comparison patients. CONCLUSION: Patients with NSCLC had higher levels of PCRS than patients with prostate cancer or breast cancer but not higher baseline levels of shame and guilt. Smoking is correlated with higher levels of guilt and shame. A belief that one caused one's own cancer is correlated with higher levels of guilt, shame, anxiety, and depression. These findings could be translated into an increased need for open communication among patients and their providers surrounding issues of cancer causation, guilt, shame, depression, and anxiety.
treatments, which typically involve many new medications, side effects, and health care provider visits.
Guilt is defined as self-conscious negative feelings about one's behavior or behavioral self-blame (eg, "I did a bad thing"). 10 In contrast, shame is defined as self-conscious negative feelings about oneself or characterologic self-blame (eg, "I am a bad person"). Although shame and guilt are associated with depression and anxiety, shame is more likely to be associated with depression or anxiety. There is also an association with social withdrawal. 11 Qualitative studies have suggested a stigma associated with a diagnosis of lung cancer, 12 but, to date, no quantitative studies have been performed, nor did any previous study include a comparison arm of patients without non-small-cell lung cancer (NSCLC). Finally, no previously reported study has used validated tools to assess levels of guilt and shame among patients with lung cancer. Understanding the levels of guilt and shame felt by patients with lung cancer is important because these emotions could affect the quality of care the patient receives and the patient's quality of life. If a difference is found, interventions could be designed and directed at physicians, caregivers, and patients to address this stigma and improve the care of patients with lung cancer.
The objectives of this study were to quantify the levels of guilt, shame, depression, and anxiety in patients with lung cancer compared with patients with breast and prostate cancer and to determine the degree to which cancer patients believe their behavior contributed to their cancer.
Patients and Methods

Participants
Any patients with stage IV NSCLC, breast cancer, or prostate cancer who could complete a survey in English were eligible to enroll. This study enrolled patients from the University of Wisconsin Oncology Clinic (an academic oncology practice), the William S. Middleton Memorial Veterans Administration oncology clinic, and the University of Wisconsin Health Oncology Clinic (a community oncology practice), all in Madison, WI. Patients were identified by their primary oncologist. The oncologists were instructed to discuss the study with any patient with stage IV lung, breast, or prostate cancer who was fluent in English. A minimal life expectancy was not required, nor were patients with a previous history of cancer excluded. If the patients were interested and agreed to be contacted, they were then consented by telephone by 1 investigator (Nicole M. Else-Quest, PhD). Data about those who refused to participate were also collected. Before initiation of this survey, the study protocol was examined and approved by the institutional review board at the University of Wisconsin Hospital and Clinics and the William S. Middleton Memorial Veterans Administration Hospital.
Survey Details
The survey was designed to take 20 minutes to complete and included validated survey tools, demographic data, and investigator-designed questions. To assess for change in emotions over time, 3 surveys were planned (at enrollment [T0], 2 months
[T1], and 6 months [T2]). Patients were allowed to complete the survey in multiple sittings, if necessary, and assistance from a friend or loved one to complete the survey was permitted. Patients' medical records were not accessed; only self-reported information was used. Demographic variables were assessed only in the first questionnaire; otherwise, the 3-questionnaire packets were identical. Whenever possible, short or abbreviated forms of measures were used in order to limit the study's energy and time burden on participants. These shortened versions have not been validated, but the internal validity on this shortened version was good (α = 0.91).
Any patient with high depression or anxiety scores or who submitted a concerning comment in the open-ended questions (eg, "I wish I were dead") were to be immediately contacted upon receipt of their survey and offered a referral to a psychologist or psychiatrist.
Demographic Variables
Participants were asked to report age, sex, ethnicity, marital status, educational attainment, and family income.
Social Support
At each assessment, participants were asked how supportive they felt their family had been of their cancer treatment. Participants answered this question on a scale from 1 (not at all supportive) to 3 (very supportive). Participants also answered the question "How often do you go to doctor appointments alone?" as a measure of social support of cancer care. This question was answered using a scale from 1 (always) to 3 (never). The 2 items were analyzed separately because of the poor internal consistency of a scale combining them (α = 0.17).
Health Status
At each assessment, participants were asked to report smoking status (current, previous, or never; start and quit date; number of packs per day smoked; and use of other forms of tobacco, such as pipe, cigar, or snuff ). They were also asked to rate their overall health (1 [poor] to 4 [excellent] ) and to report a personal history of depression or anxiety diagnoses, the date of cancer diagnosis, the cancer stage at diagnosis, and the current cancer stage.
Anxiety
The Spielberger State-Trait Anxiety Inventory (STAI) 13 assessed anxiety. The 8 items in this inventory were rated on a scale from 1 (strongly disagree) to 5 (strongly agree) regarding how participants feel at the time they complete the questionnaire. Three items are reverse scored. High scores indicate high levels of anxiety. A sample item from the STAI is "I am tense." Patients also reported if they had a previous history of anxiety.
Depression
In order to assess the amount of depressive symptoms that patients had experienced in the previous week, the Center for Epidemiological Studies Depression Scale (CES-D) was used. 14 
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The CES-D contains 20 items; 2 items thought to be confounded by cancer and its treatments were removed ("I did not feel like eating" and "My appetite was poor"). Patients rated each of the remaining 18 items on an anchored scale of frequency ranging from 0 (rarely or none of the time) to 3 (most or all of the time). The overall score is calculated by summing the ratings over 18 items, with a possible range of scores of 0-54. Higher numbers indicate more negative effects and symptoms of depression. A cutoff of 16 (using the 20-item scale) or above is generally used to indicate possible depression. A sample item is "I was bothered by things that don't usually bother me." Patients also reported if they had a previous history of depression.
State Shame and Guilt Scale
The State Shame and Guilt Scale (SSGS) assessed current levels of generalized guilt and shame. 15 The SSGS is a 10-item inventory with 5 items measuring state shame and 5 items measuring state guilt. Items were rated from 1 (strongly disagree) to 5 (strongly agree). A sample item for the shame subscale is "I feel small." A sample item for the guilt subscale is "I feel remorse, regret." The previously reported internal consistency for both subscales was good (coefficient α = 0.89 for shame, 0.82 for guilt). 11 The coefficient α for the current study was 0.9 for shame and 0.89 for guilt. These items apply to an overall sense of guilt or shame and not to one's feelings specifically about one's cancer.
Perceived Cancer-Related Stigma
Based on a focus group composed of lung cancer support group participants, the investigators developed 6 items to assess self-blame related to cancer, meant to encompass feelings of guilt, shame, and embarrassment about one's cancer. Items were rated 1 (strongly disagree) to 5 (strongly agree). Items include "I am ashamed I got my type of cancer," "I deserve my type of cancer," "People judge me for my type of cancer," "My family feels ashamed of my cancer," "I am embarrassed to tell people my type of cancer," and "My behavior contributed to my cancer." Items were averaged to create a scale of perceived cancer-related stigma (PCRS; Cronbach's α = 0.75). This panel of questions was created for this study and had not been previously validated.
Because no patients with breast or prostate cancer were part of the focus group used to design the PCRS scale, an open-ended item was added. This item read, "Many different things can cause cancer. What do you believe caused your cancer?" All responses were content analyzed and examined for distinct themes. Participants received separate codes for each theme listed. All responses were coded by 2 investigators. Inter-rater agreement on identification of specific themes was excellent (κ = 0.93-1).
Study Design
It was hypothesized that levels of PCRS, guilt, and shame would be higher in patients with lung cancer, relative to patients with breast and prostate cancer. It was also hypothesized that women with cancer would have more guilt or shame than men because of their greater propensity toward both emotions. 11 Furthermore, because of the suspected higher rates of guilt and shame, and the association of each with depression and anxiety, it was hypothesized that levels of depression and anxiety would be higher in patients with lung cancer relative to patients with breast and prostate cancer. It was thought that time since diagnosis, higher levels of education, and being married or partnered would predict for less guilt, shame, depression, and anxiety for all cancer types.
This study was designed to follow patients with stage IV NSCLC, breast cancer, or prostate cancer. The primary endpoint was the SSGS score. The target sample size for this study was 94 patients with NSCLC, 47 patients with breast cancer, and 47 patients with prostate cancer (comparison groups). The sample size was chosen to detect an anticipated difference of ≥ 0.75 points in the mean SSGS scores between patients with NSCLC and patients with breast or prostate cancer with 80% power to a 2-sided significance level of 0.05 (0.1/2, a Bonferroni adjustment for multiple comparisons [guilt and shame]), assuming a common standard deviation (SD) of 1.5 points. The rationale for using an overall significance level of 10% was the exploratory nature of this survey study and the multidimensional structure of the SSGS.
Statistics
Categoric data were summarized as frequencies and percentages. All quantitative data were summarized in terms of means and SDs. In order to examine group differences in guilt, shame, and PCRS, a 2 (sex, age) × 2 (lung cancer vs. comparison) between-subjects multiple analysis of covariance (MANCOVA) was performed with SSGS scores and PCRS scores as the dependent variables, with months since original cancer diagnosis as a covariate. To examine group differences between patients who identified past behavior as a cause of their cancer, a betweensubjects MANCOVA comparing patients with lung cancer who agreed that past behavior had contributed to their cancer with those who disagreed with the statement was performed with shame, guilt, self-esteem, anxiety, and depressed affect as dependent variables and months since original cancer diagnosis as a covariate. Residuals plots were examined to assess the normality assumption. χ 2 analysis was used to compare response patterns of individual instrument items between groups. Two-sample t tests were used to compare the mean shame, guilt, and PCRS scores between subgroups (eg, current or former smokers vs. nonsmokers). All statistical tests were 2 sided, and P < .05 was used to indicate statistical significance. Statistical analyses were performed using SPSS software, version 11.5.
Results
Participation
In total, 327 patients were approached to participate. Of those, 266 (81.3%) consented to be contacted with further information regarding the study. Those participants were contacted by telephone or mail, although 22 (8.3%) could not be reached, 20 (7.5%) died before they could be contacted, and 2 (0.8%) were ineligible for participation. Of those contacted, 22 patients (8.3%) refused to participate, saying they were uninterested or that their health was too poor. Two hundred
Noelle K. LoConte et al
Guilt and Shame in Patients with NSCLC patients agreed to participate and were enrolled in the study; 172 (86%) of them completed ≥ 1 questionnaire by August 15, 2006 (at which time, data collection ceased). Therefore, 52.6% of patients who were approached completed ≥ 1 questionnaire for this project. Data were not collected about the number of participants who required assistance in completing their survey. Ninety-four patients (47.5%) completed questionnaires at all 3 time points (52 patients with NSCLC, 28 with prostate cancer, and 14 with breast cancer). Ninety-six patients with NSCLC, 46 patients with prostate cancer, and 30 patients with breast cancer enrolled and completed ≥ 1 survey. Forty-six patients are known to have died after completing ≥ 1 survey during the study period. There was no difference in mean guilt or shame scores among patients who completed all 3 surveys versus those who did not (P > .05, data not shown). The study was closed prematurely because of poor accrual among patients with breast cancer. Patients who completed 1 or 2 surveys were not different from those who completed all surveys in age, educational attainment, income, or self-rated health at the enrollment. 66.9 years; SD ± 11.18 years). Patients with prostate cancer were significantly older than patients with breast cancer or lung cancer. Most patients (66.9%) were married or partnered, and participants came from a variety of educational backgrounds and family incomes. Cancer groups did not differ significantly on educational attainment, response to the 2 social support questions, or family income. Among patients with lung cancer, most (80.2%) were previous smokers, 11.5% reported that they were current smokers at enrollment, and 8.3% reported never having smoked. Among comparison group patients, 57.9% were previous smokers, 32.9% never smoked, and 9.2% were current smokers at enrollment. Being a smoker was associated with lower income and education (P < .05), regardless of cancer type. At T1, 11 patients (11.5%) with lung cancer, 3 patients (10%) with breast cancer, and 4 patients (8.7%) with prostate cancer reported currently smoking. At T2, 6 patients (8.5%) with lung cancer, none with breast cancer, and 3 (8.3%) with prostate cancer reported currently smoking. At T3, 5 patients (9.8%) with lung cancer, none with breast cancer, and 3 (10.3%) with prostate cancer reported currently smoking. These numbers are too small to permit a meaningful analysis of trends.
Demographics
The mean amount of time since original cancer diagnosis was 48.5 months, with great variability among the 3 cancer groups (patients with NSCLC, 14.4 months; patients with prostate cancer, 85.7 months; and patients with breast cancer, 115.8 months). Thus, in all MANCOVA analyses, months since cancer diagnosis was adjusted for.
Guilt and Shame
The mean overall SSGS score at T0 was 1.7 (SD ± 1.03) for patients with NSCLC and 1.45 (SD ± 0.81) for comparison patients (P = not significant [NS]; Figure 1 ). The mean SSGS shame subscale score at T0 was 1.49 (SD, 0.88) for patients with NSCLC and 1.38 (SD ± 0.74) for comparison patients (P = NS; Figure 2 ). There were no significant differences seen in overall guilt or shame among or within the groups over the remaining 2 time points. However, patients who identified their behavior as a cause of their cancer (scores of 4 or 5 [agree or strongly agree] to the statement "My behavior contributed to my cancer") had higher levels of guilt and shame than patients Figure 3) . Patients who were neutral (score 3) were excluded from this analysis. This exclusion was planned prospectively. Guilt and shame were highly correlated, suggesting a lack of divergent validity in the 2 subscales of the SSGS (r = 0.75; P < .0001). There was no significant difference in overall levels of guilt or shame by sex, nor was the effect of the cancer type moderated by sex in multivariate analysis (see "Impact of Sex" below). Age was not correlated with guilt or shame. The mean number of months since diagnosis was not associated with SSGS scores (P > .05).
Perceived Cancer-Related Stigma
Unlike SSGS score, which measures overall, underlying guilt and shame, there was a difference in perceived cancerrelated guilt and shame between the patients with NSCLC and the comparison patients. The mean PCRS score was 1.93 (SD ± 0.85) among patients with NSCLC and 1.45 (SD ± 0.49) among comparison patients (P < .01). Patients with lung cancer were significantly more likely to agree with the following statements: "I am ashamed I got my type of cancer," "My family feels ashamed of my type of cancer," "I am embarrassed to tell people my type of cancer," and "My behavior contributed to my type of cancer." However, patients with NSCLC did not agree with the statements "I deserve my type of cancer" or "People judge me for my type of cancer" any more frequently than comparison patients (Table 2 ). For patients with lung cancer and comparison patients, overall guilt and shame were each correlated with PCRS score (P < .01 for both). A longer amount of time since diagnosis was associated with lower PCRS scores (P < .01).
Depression and Anxiety
The mean depression score for patients with NSCLC at T0 was 10.29 (SD ± 9.15) versus 9.16 (SD ± 8.7) for comparison patients (P = NS). At T1, 21.5% (n = 37) met the CES-D criteria for depression; at T2, 14.5% met criteria; at T3, 10.5% met CES-D criteria for depression. Twenty eight of 95 patients (29.5%) with NSCLC, 12 of 30 patients (40%) with breast cancer, and 10 of 46 patients (21.7%) with prostate cancer reported a history of being treated for depression/anxiety. The groups were not significantly different in likelihood of depression history. Current or previous smokers were no more likely to report a history of depression than nonsmokers. A quadratic trend for each type of cancer was observed (P < .05) with depression, such that the depressive symptoms of patients with lung cancer peaked at 2 months, and comparison group patients' depressive symptoms peaked at 6 months. Anxiety scores at T0 were not significantly different between groups (mean, 2.36 [SD 1.03] vs. 2.16 [SD ± 0.94] for the NSCLC and comparison group, respectively). Patients with lung cancer showed a linear (P < .05) increase in anxiety over the 6-month period, whereas comparison group patients did not. There were significantly higher levels of depression and anxiety observed in patients who identified their previous behavior as contributing to their cancer ( Figure  3) . A higher mean time since diagnosis was correlated with lower rates of anxiety and depression (P < .01).
Impact of Sex
There were no significant differences in SSGS, PCRS, or depression scores between men and women (data not shown). However. there was a difference seen at T1 in anxiety scores, with women indicating higher levels of anxiety (men 2.05, women 2.49; P < .01).
Impact of Smoking
Smoking status was significantly associated with the experience of guilt and shame among patients. Current and previous smokers with lung cancer had higher mean guilt and shame scores (1.75 [SD ± 1.05]) than nonsmokers (1.08 [SD ± 0.21]; P = .024). Twenty-nine point five percent of patients with NSCLC and 10.5% of comparison patients reported that their past behaviors contributed to their cancer. For comparison patients, a history of smoking was correlated with higher guilt and shame scores (P < .05). In addition, for patients with lung cancer only, a previous or current history of smoking correlated with higher PCRS scores.
Open-Ended Question
In response to the question "What do you believe caused your cancer?" the most frequent response was "I don't know." Patients with breast and prostate cancer were more likely than patients with lung cancer to state that they did not know what caused their cancer (P < .01). The next most frequent response was smoking, which was reported by a majority of patients with lung cancer but only 1 comparison cancer patient. Environmental causes, such as pollution or asbestos, were reported by 20.8%
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Discussion
Lung cancer is largely the result of smoking or exposure to smoke. Thus, a patient with lung cancer could be more apt to feel a stigma for a behavioral choice, leading to guilt or shame. Health care providers could also be more likely to blame patients for their lung cancer because they smoked. These negative feelings could impair patients' self-esteem or impair the effectiveness of the treatments or the quality of the patients' care. One previous qualitative study has confirmed the stigma felt by patients with lung cancer. 12 Other studies have confirmed the bias against patients with lung cancer and smokers by health care providers. 16, 17 This study is the first to quantitatively assess levels of guilt and shame in patients with NSCLC compared with patients with cancers that are largely unrelated to lifestyle choices (breast and prostate cancer). Although there were no differences in the overall SSGS scores between patients with lung cancer and the comparison group of patients with breast and prostate cancer, there were significant differences in the PCRS scale score. In addition, the mean SSGS scores were not different from scores obtained from a college student control group, 11 suggesting that patients with lung cancer do not have more overall guilt or shame. In addition, but not surprisingly, patients with lung cancer were more likely to agree that their behavior contributed to their cancer than were the comparison patients.
Patients with lung cancer who identify past behavior as a cause of their cancer are more likely to express higher levels of guilt, shame, anxiety, and depression. Interestingly, a large number of patients with lung cancer do not believe that their behavior contributed to their cancer, and this belief could be advantageous to their mental health in that it could allow them to avoid negative feelings of guilt, shame, depression, and anxiety. Generally, cancer survivors tend to underestimate the role of behavior in contributing to cancer etiology, 18 and smokers tend to underestimate their risk of developing lung cancer from smoking. [18] [19] [20] [21] [22] [23] These results suggest that effective care of a patient with lung cancer can include resolving feelings of guilt or shame about one's smoking history. Mitigating psychological distress (such as guilt, shame, depression, and anxiety) can happen at any point in a cancer patient's care but can be of particular importance during the transition from cancer-directed therapies to palliative care, and it can be important not just for patients with lung cancer, but for patients with breast or prostate cancer as well because of the relatively higher levels of depression and anxiety seen in this sample. Improving communication among patients, caregivers, and cancer therapy providers can also help to relieve some of this distress.
There are several limitations to the current research. Although we tried to craft the PCRS items to apply to many different kinds of cancer, their initial development was performed without input from breast or prostate cancer survivors.
To attempt to control for this, we included an open-response question for patients to answer if they wished, but they might not have included all emotions in this response. We were unable to complete the breast cancer cohort, and thus correlations between women with lung or breast cancer or stronger sex differences could have been missed. The reasons for this poor accrual among breast cancer are unclear; we were able to accrue nearly equal numbers of men and women to the lung cancer cohort without difficulty. Our study included very few nonsmokers for comparison. Although our patient population was diverse in terms of age, education, and socioeconomic status, it consisted largely of white patients from smaller towns and rural areas in Wisconsin; it is possible that results might have been different had we surveyed large urban areas. This study allowed for a loved one or friend to assist the participant with completion of the survey, a necessity because of the weakness that frequently accompanies metastatic cancer. However, this might have compromised a participant's willingness to admit to negative self-emotions, such as guilt, shame, depression, or anxiety. The statistical power for the third survey (at 6 months after enrollment on study) is lessened because over half of the patients did not complete the survey or did not survive to that time point. In addition, the longer period of time that the comparison group had been diagnosed with their cancer relative to the lung cancer group might have affected their ability to "come to terms" with their cancer diagnosis and might have affected psychological health. The SSGS did not allow us to differentiate between guilt and shame with confidence. It is possible that one emotion over the other predominates in patients with lung cancer. We did not collect data on whether participants had a previous history of cancer before their current diagnosis, which can influence the response to the current cancer. We also did not include a measure of the patients' current symptoms and cannot exclude the possibility that their anxiety or depression is not related to emotions surrounding their cancer diagnosis but to the accompanying symptoms.
Conclusion
We conclude that patients with lung cancer feel increased levels of PCRS, but do not have higher levels of baseline shame and guilt. Levels of guilt, shame, and PCRS did not change over time and were not different by sex. However, guilt and shame were affected by smoking, with current and former smokers having higher levels of both emotions, regardless of tumor type. In addition, relatively few patients with NSCLC in our cohort felt that their behavior contributed to the development of their cancer, and this belief was correlated with better outcomes.
Further research is indicated to determine if these feelings affect the ability of patients with NSCLC to self-advocate and whether intervening their feelings of self-blame, depression, or anxiety will improve their self-esteem and cancer outcomes. Similar research should be performed on patients with earlier-stage lung cancer; perhaps with their relatively better prognosis, there would be more patients able to complete all 3 surveys over 6 months.
Based on these data, we suggest that health care providers who care for patients with lung cancer seek out opportuniNoelle K. LoConte et al ties to discuss underlying feelings of guilt or shame about a patient's diagnosis, and to address underlying feelings of depression and anxiety.
